Results 251 to 260 of about 117,497 (280)

MLLT1 (myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 1)

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2010
Jl Huret
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature

AJSP: reviews & reports, 2019
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by a reciprocal translocation, t(9;22) (q34.1;q11.2). This leads to fusion of the BCR and ABL1 genes, encoding an active tyrosine kinase that causes unregulated ...
A. Ware, L. Wake, P. Brown, Jonathan A. Webster, B. Smith, A. Duffield   +5 more
semanticscholar   +1 more source

Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia

Leukemia and Lymphoma, 2022
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinics for risk calculation and treatment decisions.
Tugce Sudutan, Y. Erbilgin, Ozden Hatırnaz Ng, S. Karaman, Z. Karakaş, Fulya Kucukcankurt, T. Celkan, Ç. Timur, G. Ozdemir, Şadan Hacısalihoğlu, S. A. Gelen, M. Sayitoglu   +11 more
semanticscholar   +1 more source

Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia

Advances in Materials
Hematological malignancies (HM) like acute myeloid leukemia (AML) are often intractable. Cancer vaccines possibly inducing robust and broad anti‐tumor immune responses may be a promising treatment option for HM.
Peng Zhang, Tanzhen Wang, Guanhong Cui, Ruonan Ye, Wenjun Wan, Tianhui Liu, Yiran Zheng, Z. Zhong   +7 more
semanticscholar   +1 more source

Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

Nature Cancer
Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherein primitive AML
Carl Sandén, Niklas Landberg, Pablo Peña-Martínez, Hanna Thorsson, S. Daga, Noelia Puente-Moncada, Maria Rodriguez-Zabala, Sofia von Palffy, Marianne Rissler, V. Lazarevic, Gunnar Juliusson, Mats Ohlin, Axel Hyrenius-Wittsten, Christina Orsmark-Pietras, H. Lilljebjörn, Helena Ågerstam, T. Fioretos   +16 more
semanticscholar   +1 more source

CRISPR/Cas9-mediated t(4;11) translocation in human hematopoietic stem/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage

Leukemia
The chromosomal translocation t(4;11)(q21;q23) is frequently diagnosed in KMT2A-r Acute Leukemia patients. Although we understand much about the function of both wildtype KMT2A and AFF1 multiprotein complexes, little is known about the molecular actions ...
T. Benz, P. Larghero, C. Meyer, T. Hanewald, D. Brüggmann, A. Hentrich, F. Louwen, R. Marschalek   +7 more
semanticscholar   +1 more source

Evaluation of some genes and proteins involved in apoptosis on human chronic myeloid leukemia cells (K562 cells) by datura innoxia leaves aqueous extract

Journal of Biomolecular Structure and Dynamics, 2019
Datura innoxia (D. innoxia) has an extensive usage in traditional medicine and can also be used for intervention therapy in order to treat cancer. Despite of accomplishing some researches on D.
Elham Chamani, Z. Rezaei, Kazem Dastjerdi, S. Javanshir, Khatereh Khorsandi, G. Mohammadi   +5 more
semanticscholar   +1 more source

Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia

Blood Advances
Asciminib (ASC) is an allosteric inhibitor of BCR::ABL1 that binds the myristoylation site of the ABL1 protein. We report the use of ASC in relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of ...
M. Chanut, Aurélie Cabannes-Hamy, M. Balsat, N. Sahki, E. Raffoux, Y. Hicheri, B. Lioure, Lucie Laemmel, T. Leguay, V. Cacheux, M. Gallego-Hernanz, Andréa Pieragostini, G. Roth-Guepin, Ludovic Gabellier, N. Denizon, L. Willems, Quentin Cabrera, S. Chantepie, Valérie Coiteux, Claudie Capdupuy, Martin Carré, A. Machet, Juliette Lambert, Sandrine Roux, F. Nicolini, N. Boissel, E. Clappier, R. Kim, P. Rousselot   +28 more
semanticscholar   +1 more source

Effect of Clathrin Assembly Lymphoid Myeloid Leukemia Protein Depletion on Clathrin Coat Formation

Traffic : the International Journal of Intracellular Transport, 2005
Anika Meyerholz, L. Hinrichsen, S. Groos, P. Esk, G. Brandes, E. Ungewickell   +5 more
semanticscholar   +1 more source

TCR-T cells expressing a TCR recognizing the MPO propeptide-derived MPO132-140:HLA-a*02:01 specifically kill AML and spare healthy myeloid cells

Blood
Patients with AML/MDS have limited therapeutic options. While antigen-specific T cell therapies (e.g. CAR-T) have shown curative potential in treating lymphoid leukemias, their use to treat myeloid leukemia has been challenging. This is despite the
Yibin Chen, Yanqing Huang, Xizeng Mao, Shoudan Liang, Priya Koppikar, Noah J Tubo, J. Molldrem   +6 more
semanticscholar   +1 more source